Stockscreener 앱 받기
38.44
2.70%
1.01
시간 외 거래:
38.50
0.06
+0.16%
Exelixis Inc 주식(EXEL)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - The Globe and Mail
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga
Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada
Citizens JMP reiterates Exelixis stock with $41 target - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
(EXEL) Investment Analysis - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com
Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India
Guggenheim maintains Exelixis stock with $42 target - Investing.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - Yahoo
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
0.19%
자본화:
|
볼륨(24시간):